This is how Glaxo hid data and fooled us all

Glaxo did hide data from the regulators and the public about Seroxat/Paxil – for those of you that are new to all this here’s what they did and how they did it:

Secret e-mails show that one of the world’s biggest drug companies distorted clinical trial results of their anti-depressant Seroxat, covering up a link with suicide in teenagers. On Monday January 29, 2007, the BBC TV programme Panorama showed shocking footage demonstrating how GlaxoSmithKline’s PR people and marketing department ‘spun’ devastating trial results on children which showed serious risk of suicide, self-harm and aggression (violence), and also indicated it was no more effective than a sugar pill. Instead they claimed to doctors that the drug was ‘remarkably’ safe and effective for under-18s, with the support of an ‘independent’ professor of psychiatry who earned $500,000 in fees from drug companies in one year.

Seroxat, marketed in the US as Paxil, an SSRI anti-depressant whose active ingredient is paroxetine, was a big success for GlaxoSmithKline (GSK) from its release in the 1990s, earning billions of dollars worldwide for the drug giant. With a strategy of creating new markets for the drug, in the mid-1990s GSK began to explore the possibility of obtaining a licence for its use in children (under-18s), and conducted clinical trials on groups of children to provide data proving its effectiveness which would support its application.

However, the trials were a bust, in particular Study 329, the biggest of a series carried out over a period of years in the US. The results of Study 329 demonstrated that Seroxat had no measurable benefit to child patients. As is usual in the so-called gold standard clinical trial approach, the drug was tested on one group while another was administered a placebo, a sugar pill with no active ingredient. Neither group, nor the administrators of the pills, knew which pill they were getting.

The group given the placebo performed just as well, or as badly, as those given Seroxat in terms of the trial designers’ criteria for improvement in their depression.

But the children who were given Seroxat suffered adverse reactions ranging from mild to serious. The serious adverse reactions included self-harm — mostly cutting; aggression — violence to others; and suicidality — suicidal thoughts or actions, meaning actual suicide attempts.

Seven out of the 93 children in the Seroxat group had to be hospitalised as a result. That’s almost eight per cent. To independent researchers, that would be a wildly unacceptable proportion of a treatment population.

In terms of risk, for example, a prevalence of an adverse drug reaction of one in one hundred, one per cent, or more is defined as ‘frequent’ and seen as unacceptable.

Yet Seroxat had put eight in one hundred in hospital in this clinical trial.

“This was the point at which GSK should have begun warning physicians who were prescribing the drug to children because not only is it not effective, it’s not safe,” says Karen Barth Menzies, the California lawyer heading the team pursuing a giant class action suit against GSK in America. Menzies possesses previously secret internal memos and e-mails from GSK, obtained as part of the disclosure process for the upcoming trial, which show what actually happened next.

The company dropped the plan to apply for a licence for the use of Seroxat in children. Its executives immediately recognised that the results of Study 329, which demonstrated no efficacy in treating adolescent depression, would ensure that no licence would be granted. In an internal company memo dated 14 October 1998, they concluded that the drug does not work and that a licence application would be refused: ‘The results of the study were disappointing. The possibility of obtaining a safety statement was considered, but rejected.’ The best they felt they could achieve was a ‘ statement that although safety data was reassuring, efficacy had not been demonstrated’.

‘Efficacy had not been demonstrated’ is a fancy way of saying that the drug did not work, and they knew it. ‘The possibility of obtaining a safety statement was considered, but rejected’ means they realised that the extent of adverse reactions in the trial, at 8%, meant the drug was not safe.

GSK marketing teams commented that ‘the data would be unacceptable commercially’. Panorama’s reporter Shelley Jofre translates this as ‘publishing the data in full would put profits at risk’.

Enter the spin doctors.

So the self-harm, aggression and suicide attempts were kept quiet, the lack of effectiveness filed away. PR people took over to implement a new plan: promote Seroxat to doctors as a treatment for under-18s.

How could this be? If it’s not been granted a licence, how can a drug be prescribed? Unfortunately, as Panorama explained, even if a drug is not licensed for a particular group doctors can still prescribe it if they think it will benefit their patient — so-called ‘off-label’ prescribing.

So GSK’s plan was simple — persuade doctors that Seroxat was indeed suitable for their child patients. Which they duly put into effect, spinning the exact opposite of what the studies had shown: Seroxat, they said, was ‘remarkably effective and safe for children’.

Enter the academic psychiatrists, notably Professor Martin Keller of America’s Brown University and child psychiatrist Dr Neal Ryan of the University of Pittsburgh, both co-authors of Study 329.

Panorama questions whether Keller is independent in any sense. The programme pointed out that in one year he earned $500,000 in fees from drug companies including GSK. Worse, it demonstrates that his paper on Study 329, published in the Journal of the American Academy of Child and Adolescent Psychiatry, which says it ranks as number one in child mental health in the world, ‘was written by a ghost writer who worked for a PR company, a PR company hired by GSK’. And it quoted an e-mail from Keller to the ghost writer, thanking him for his work: ‘You did a superb job with this. Thank you very much. It is excellent. Enclosed are some rather minor changes from me…’

The ghost had even penned Keller’s covering letter submitting the paper to medical journals.

Child psychiatrist Neal Ryan was paid by GSK as a co-author of Study 329. In 2002 he gave a talk on childhood depression at a medical conference in Toronto sponsored by GSK, attended by 15,000 psychiatrists. He said that Seroxat could be a suitable treatment for children and later told Shelley Jofre that it probably lowered rather than raised suicide rates.

And among the archive of documents in the lawyers’ possession, Jofre found the evidence that Ryan had forwarded to GSK her own e-mails to him from 2002 asking questions about the safety of Seroxat. His covering e-mail asked the company for advice on how to respond to her queries.

Nonetheless, the paper, of which Keller and Ryan claimed authorship, was published — but not before one journal turned it down after its peer reviewers found serious flaws, notably the downplaying of adverse reactions to Seroxat among the children trialed.

Last year, Professor Keller admitted to lawyers suing GSK that he had not studied the results of Study 329 in full. “I reviewed data analytic tables. I don’t recall how raw it [the data] was. [These are] huge printouts, you know, item by item numbers and variable numbers, and don’t even have words on them. I tend not to look at those… I do better with words than I do with symbols,” he recounted in a session recorded on video. In effect, he admitted that his ‘authorship’ of the paper, apart from being written by a PR company’s ghost, was based on at best an inadequate and incomplete scrutiny of the data — hardly the gold standard scientific review we are constantly told validates clinical trials.

Says Karen Barth Menzies: “These academics are truly spokespersons for the drug companies.”

But the drug company in question, GlaxoSmithKline, buried the trial data, including data from another, later trial on children which found that the placebos given to the control group of depressed kids ‘worked’ better than Seroxat. And later, forced by US medicines regulator the FDA to re-evaluate the raw data from Study 329, the company admitted to four further adverse reactions in which children became suicidal, raising the number suffering severe reactions to the drug from seven to 11 — a shocking 12 per cent of the total, and representing a 600% increase in events related to suicide.

Memos in the lawyers’ boxes of GSK papers show that company executives clearly told the PR woman who designed their spin strategy that ‘Seroxat may have caused all of these’. Yet the final article, approved by the PR, stated: ‘Of the 11 patients, only headache (one patient) was considered to be related to the treatment’ and concluded that the drug was ‘generally well tolerated and effective’. This was, finally, reviewed by and accepted for publication in the Journal of the American Academy of Child and Adolescent Psychiatry. And it was published relatively unchanged, even though the journal’s peer reviewers objected in these terms: ‘Overall, results do not clearly indicate efficacy. Authors need to clearly note this.’ ‘The relatively high rate of adverse effects was not addressed in the discussion (core portion of an academic paper)’ ‘Given the high placebo response rate, are these drugs an acceptable first-line therapy for depressed teenagers?’

Though the article appeared, GSK abandoned a part of its PR plan which intended to use it extensively in publicising Seroxat’s use with children. At company headquarters in Britain, a PR executive commented: ‘Originally we had planned to do extensive media relations surrounding this study until we actually viewed the results. Essentially, the study did not show [Seroxat] was effective in treating adolescent depression, which is not something we want to publicise.’

After publication, the third of GSK’s trials reported that the placebo worked better than Seroxat. The company’s public claims had been flatly contradicted by its own trial, but it maintained a deafening silence on this, telling doctors instead that Study 329 showed the drug ‘was superior to placebo by several assessment methods’. The two failed studies were not mentioned either when GSK informed its US sales force that Seroxat/Paxil ‘demonstrates remarkable efficacy and safety in the treatment of adolescent depression’.

“They didn’t tell the regulators or physicians or parents about these risks or the lack of efficacy. Instead, they went out and promoted this specific study as remarkably effective and safe for kids,” says Menzies. “That’s a lie. A fraud.”


12 Responses to “This is how Glaxo hid data and fooled us all”

  1. squirrel Says:

    ‘Originally we had planned to do extensive media relations surrounding this study until we actually viewed the results. Essentially, the study did not show [Seroxat] was effective in treating adolescent depression, which is not something we want to publicise.’
    It does not treat depression PERIOD ! just cause it along with many many more unpleasant symptoms.thewhole thing is a total sham and makes me sick!!!!!

  2. Lynn Says:

    All this has to considered a crime against children. It seems that prosecutors or someone has a problem with being able to consider big guys in expensive suits criminals. We need to find a way to change that.

  3. Lynn Says:

    Stephen Barrett, M.D. says
    “The FDA defines health fraud as ‘the promotion, for profit, of a medical remedy known to be false or unproven'”
    There should be hope of getting Glaxo in the U.S., particularly in light of the horrifying stories on the news about young mass murderers suffering from what Dr. Glenmullen calls ssri-withdrawal.


    A great piece of reporting Mr Admin, I take my hat off to you sir.

    The MHRA investigation took four years to complete… they must have looked at every single loophole to save GSK’s ass.

    A million pages of paperwork to sift through?

    I’ve trawled more internet pages in one year that could have told me GSK were lying.

    One small bit of hope though.

    A good, reliable source tells me that the story was leaked to the press – so the MHRA have a mole. Let’s hope this mole will come forward in the future and spill the beans on this sham of an investigation!

    Any young adults out there that took this bastard drug when they were in their teens?

    Sue the fuckers

    Rant over


  5. Eik Corell Says:

    I’m on this drug… the plan is to take me off of it in about a month from now. I’m 19, soon to be 20, and I’ve been on it for about 3 to 4 years now… Christ, the ironic thing is – I was the one who recommended this drug. I found it under the name Paxil, and it turns out the doctor took my lowly advice after the first pills I took were no good. I’m actually very scared about going off of them, because I’ve seen other reports from my native country confirming a lot of the problems mentioned — Mainly that it’s hard to get off of it. What stunned me was the whole thing that they have no effect on adolescents… because I think they had an effect on my back then and to this day. But I guess that’s the way it is with drugs – You never know if it’s just placebo, at least I don’t. I truly hope it was now because after seeing the accounts of people who’ve tried / succeeded in getting off of it don’t wanna go back to feeling like crap if it can be avoided, but all the signs are telling me to get off this stuff.
    And now I run into another website about this drug that my doctor trivialized so much – Apparently it shouldn’t be a problem unless you slowly stop taking them.

    God help me, I really didn’t know that this drug was that dangerous.

  6. Lynn Says:

    Actually, you’re supposed to stop taking them slowly. Your library might have a copy of the book The Antidepressant Solution by Joseph Glenmullen. He tells people what to look for to see how slowly they have to taper off many brain drugs. You should try to get a copy of it to your doctor before you start lowering your dose.
    Good luck, and don’t be afraid to bother people around you if things seem to be going badly.

  7. Lynn Says:

    Actually, you’re supposed to stop taking them slowly. The book The Antidepressant Solution by Joseph Glenmullen explains what patients need to know while they’re getting off this drug. Good luck, and try not to assume that you will be one of the ones who get hurt so badly. You may not be.

  8. truthman30 Says:

    The MHRA should be controlled by the government not Pharma..
    This corporate murder of kids by GSK was a loop hole waiting to be exploited..
    What a joke..

  9. Yet more on Paxil Study 329, Keller et al « seroxat secrets… Says:

    […] you need to catch up on Study 329, then read this. Otherwise just carry […]

  10. Open letter to Paul Blackburn, GlaxoSmithKline « seroxat secrets… Says:

    […] Do you mean the way that GSK did not release negative paediatric trial data (Seroxat/Paxil – Study 329), but rather spun the data and used it to promote the sales of Seroxat/Paxil? […]

  11. Andrew Witty admits defeat on “expensive, high risk” depression drugs « seroxat secrets… Says:

    […] Or maybe Seroxat didn’t actually work any better than a sugar pill… maybe the ‘chemical cure’ was a lie… maybe Glaxo had no idea how Seroxat was supposed to work… maybe the side effects are much, much worse than Glaxo admitted… maybe Glaxo faked drug trial results and hid the negative data… […]

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: